ABOUT US

MD, PhD, FASN, FAST, Professor Haraldsson has served for 15 years as Chair of nephrology at the University of Gothenburg, Sweden, and as senior consultant at the nephrology clinic at Sahlgrenska University hospital, Gothenburg. Most recently, he initiated and lead high-profile global drug development projects in nephrology, transplantation, and rheumatology at Novartis, Switzerland. Read more about Börje Haraldsson here.

MBA, PhD in Clinical Nephrology focused Pharmacokinetics. Pål Falck has a broad background within the life science sector including Nordic Medical Director in Oncology & Infections at AstraZeneca, Medical Advisor and Business Development at Pfizer Norway, Healthcare Equity Research Analyst at Arctic Securities in Norway.

PhD in Clinical Immunology Karolinska Institute, PMP. Susanna Dahlgren has a long experience in drug development from various positions in the pharmaceutical industry including Astrazeneca, ALK, Polypeptide, Aqilion and SDS Life Science, focusing on project leadership from early drug discovery to clinical development, medical affairs and scientific marketing. Read more about Susanna Dahlgren here.

MD, PhD in clinical pharmacology. Associate Professor Hanjing Xie is triple board certified in Clinical Oncology, Internal Medicine and Hematology and has 31 years of accumulated experience in clinical, research and drug development. Before expanding her horizons in the pharma industry, Hanjing Xie served as senior consultant at Karolinska University Hospital. In the life science sector, Hanjing Xie has taken various senior leading positions at both big pharma and small biotech companies including Bayer, Oncopeptides, Idogen, Kancera, and NeoGap.

MSc Pharm from Uppsala University. Åsa Holmgren has over 30 years of experience in Global Strategic Regulatory Affairs and Drug Development in pharmaceutical companies. She has held leadership positions and led regulatory strategies at Medivir AB, Orexo AB, AstraZeneca R&D, Pharmacia & Upjohn R&D, and Roche AB. Read more about Åsa Holmgren here.

Biochemist by training and brings extensive commercial and business development experience from the global pharmaceutical corporations Pharmacia and Ferring where he has held executive positions in Europe, the US, and Japan. Previously, Venture Partner and Partner at Sunstone Capital in Denmark. Currently, Managing Partner and Board member of Eir Ventures Partners AB.

MD, PhD, co-founder of HealthCap, Managing Partner since 1996. Previous experience includes leading ABB Aros Securities Health Care Equity Research Team. Extensive board experience from the life science sector including Q-Med AB, NicOx SA, Jerini AG, Nordic Nanovector ASA and BoneSupport AB.

M.Sc in Engineering Physics from Lund University with extensive investment and startup experience, both operationally and as board member. Currently partner in Fåhraeus Startup and Growth, privately held early-stage investment fund. Previously 10+ years responsible for innovation, start-up and investment activities at Lund University, and 15+ in the tech and telecom industry with positions in, e.g. Ericsson and ARM.

MSc in Economics and Business from Stockholm School of Economics and brings extensive experience from corporate development in Life Science companies. Experience from executive positions in several Life Science focused investment companies. Currently CFO of Linc AB, a listed investment company focused on product-oriented Life Science companies, where he also is part of the investment team responsible for evaluating new investments as well as supporting existing portfolio companies. Previously he was responsible for the investment activities of MedCap AB and prior to that he worked with corporate finance advisory at Morgan Stanley and UBS Investment Bank in London and Stockholm.